Published in J Invest Dermatol on January 10, 2008
Non-AIDS associated Kaposi's sarcoma: clinical features and treatment outcome. PLoS One (2011) 1.19
Non-AIDS-related Kaposi's sarcoma: A single-institution experience. World J Clin Oncol (2013) 0.85
Potent antiviral activity of topoisomerase I and II inhibitors against Kaposi's sarcoma-associated herpesvirus. Antimicrob Agents Chemother (2011) 0.83
Herpesvirus infections of the central nervous system in immunocompromised patients. Ther Adv Neurol Disord (2012) 0.81
Case Report: Pulmonary Kaposi Sarcoma in a non-HIV patient. F1000Res (2015) 0.79
Classic Kaposi's sarcoma in Morocco: clinico-epidemiological study at the National Institute of Oncology. BMC Dermatol (2011) 0.78
Corticosteroid Induced, HHV-8 Positive Kaposi's Sarcoma in a Non-HIV Elderly Patient. J IMA (2012) 0.78
An Update on Kaposi's Sarcoma: Epidemiology, Pathogenesis and Treatment. Dermatol Ther (Heidelb) (2016) 0.75
Trends in Kaposi's Sarcoma in Miami Beach from 1987 to 2007. ISRN Oncol (2012) 0.75
Quasi-Complete Response of Classic Kaposi's Sarcoma Treated with Weekly Paclitaxel. Case Rep Oncol Med (2013) 0.75
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78
Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med (2005) 5.54
Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med (2005) 4.83
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet (2009) 4.25
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst (2005) 4.25
HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases. Am J Hematol (2008) 3.21
Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol (2008) 3.21
Microseizures and the spatiotemporal scales of human partial epilepsy. Brain (2010) 2.81
Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat Genet (2010) 2.61
A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res (2005) 2.60
Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J Antimicrob Chemother (2008) 2.52
Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res (2004) 2.47
Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma-associated herpesvirus. Nat Genet (2004) 2.47
Four-year outcome of a prospective randomised trial comparing bipolar plasmakinetic and monopolar transurethral resection of the prostate. Eur Urol (2009) 2.42
Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol (2008) 2.38
Calcitriol: a better option than vitamin D in denosumab-treated patients with kidney failure? Expert Opin Biol Ther (2012) 2.27
British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med (2012) 2.24
Are abstracts presented at the EAU meeting followed by publication in peer-reviewed journals? A critical analysis. Eur Urol (2006) 2.11
Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. J Natl Cancer Inst (2007) 2.11
Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood (2009) 2.07
The need to reduce patient discomfort during transrectal ultrasonography-guided prostate biopsy: what do we know? BJU Int (2005) 2.07
Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res (2002) 2.01
An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples. Expert Opin Pharmacother (2011) 2.01
Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: from biological principles to clinical guidelines. Expert Opin Ther Targets (2012) 1.99
Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. Eur Urol (2008) 1.91
HIV-associated monoclonal gammopathy: a retrospective analysis of 25 patients. Clin Infect Dis (2006) 1.88
Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial. Lancet Oncol (2005) 1.84
Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy. PLoS Genet (2011) 1.80
The Presentation, Diagnosis, and Treatment of Sexually Transmitted Infections. Dtsch Arztebl Int (2016) 1.77
Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study. AIDS (2002) 1.74
The ephrin receptor tyrosine kinase A2 is a cellular receptor for Kaposi's sarcoma–associated herpesvirus. Nat Med (2012) 1.72
Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS (2007) 1.72
Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma: higher incidence and mortality in Africa than in the UK. AIDS (2013) 1.71
The growing problem of non-AIDS-defining malignancies in HIV. Curr Opin Oncol (2006) 1.69
AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy. Oncologist (2005) 1.69
Fifty years of multicentric Castleman's disease. Acta Oncol (2004) 1.65
The rising challenge of non-AIDS-defining cancers in HIV-infected patients. Clin Infect Dis (2012) 1.62
Kaposi sarcoma in unusual locations. BMC Cancer (2008) 1.60
The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature. Eur Urol (2011) 1.59
EGFR mutational status in penile cancer. Expert Opin Ther Targets (2013) 1.57
Human immunodeficiency virus-associated prostate cancer: clinicopathological findings and outcome in a multi-institutional study. BJU Int (2008) 1.55
HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era. J Clin Oncol (2012) 1.55
Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. Clin Cancer Res (2003) 1.55
Human immunodeficiency virus-associated hemophagocytosis with iron-deficiency anemia and massive splenomegaly. Clin Infect Dis (2003) 1.54
Pre-micro RNA signatures delineate stages of endothelial cell transformation in Kaposi sarcoma. PLoS Pathog (2009) 1.53
Time for oncologists to opt in for routine opt-out HIV testing? JAMA (2010) 1.53
Primary esophageal carcinoma in the era of highly active antiretroviral therapy. Arch Intern Med (2010) 1.52
Characterization of the GNAQ promoter and association of increased Gq expression with cardiac hypertrophy in humans. Eur Heart J (2008) 1.52
Identification of a correlation between Helicobacter pylori infection and Graves' disease. Helicobacter (2010) 1.52
Excessive increase in left ventricular mass identifies hypertensive subjects with clustered geometric and functional abnormalities. J Hypertens (2007) 1.52
Narrowband UVB phototherapy in skin conditions beyond psoriasis. J Am Acad Dermatol (2005) 1.51
Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin. J Acquir Immune Defic Syndr (2005) 1.50
Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS. Pharmacogenet Genomics (2012) 1.50
Evaluation of concentric left ventricular geometry in humans: evidence for age-related systematic underestimation. Hypertension (2004) 1.49
Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res (2011) 1.48
KSHV-encoded miRNAs target MAF to induce endothelial cell reprogramming. Genes Dev (2010) 1.48
Novel cellular genes essential for transformation of endothelial cells by Kaposi's sarcoma-associated herpesvirus. Cancer Res (2005) 1.48
Detection of JC virus DNA and proteins in the bone marrow of HIV-positive and HIV-negative patients: implications for viral latency and neurotropic transformation. J Infect Dis (2009) 1.46
Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study. Eur Urol (2007) 1.46
Economic evaluation of everolimus versus sorafenib for the treatment of metastatic renal cell carcinoma after failure of first-line sunitinib. Value Health (2011) 1.46
Plasma HHV8 DNA predicts relapse in individuals with HIV-associated multicentric Castleman disease. Blood (2011) 1.46
Merkel cell polyomavirus DNA in persons without merkel cell carcinoma. Emerg Infect Dis (2009) 1.45
Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer. Mol Cancer Ther (2012) 1.44
Thrombotic complications in patients infected with HIV in the era of highly active antiretroviral therapy: a case series. Clin Infect Dis (2004) 1.44
Weekly docetaxel and vinorelbine (VIN-DOX) as first line treatment in patients with hormone refractory prostate cancer. Eur Urol (2004) 1.43
Spectrum of human papillomavirus-related dysplasia and carcinoma of the anus in HIV-infected patients. AIDS Read (2005) 1.43
Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control study. J Acquir Immune Defic Syndr (2004) 1.42
HIV/AIDS: epidemiology, pathophysiology, and treatment of Kaposi sarcoma-associated herpesvirus disease: Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease. Clin Infect Dis (2008) 1.42
The Kaposi's sarcoma-associated herpesvirus K12 transcript from a primary effusion lymphoma contains complex repeat elements, is spliced, and initiates from a novel promoter. J Virol (2002) 1.41
Expression of HECA-452 antigen correlates with disease relapse in mycosis fungoides. Anal Quant Cytol Histol (2008) 1.40
13C-methionine breath test detects distinct hepatic mitochondrial dysfunction in HIV-infected patients with normal serum lactate. J Acquir Immune Defic Syndr (2005) 1.40
Thalidomide in combination with oral daily cyclophosphamide in patients with pretreated hormone refractory prostate cancer: a phase I clinical trial. Cancer Biol Ther (2007) 1.40
Images in HIV/AIDS. Sweet syndrome and syphilis in an HIV-infected person. AIDS Read (2008) 1.39
HIV infection masquerading as monoclonal gammopathy of undetermined significance. N Engl J Med (2003) 1.39
HPV-73- and HPV-82 positive anal margin carcinoma with secondary ulcerating Herpes simplex-virus 2 infection. J Dtsch Dermatol Ges (2010) 1.38
HHV8 is not limited to Kaposi's sarcoma. Mod Pathol (2005) 1.38
Left ventricular geometry in children with mild to moderate chronic renal insufficiency. J Am Soc Nephrol (2005) 1.36
Toll-like receptor 4 mediates innate immunity to Kaposi sarcoma herpesvirus. Cell Host Microbe (2008) 1.35
A meta-analysis of transient elastography for the detection of hepatic fibrosis. J Clin Gastroenterol (2010) 1.34
A prognostic index for AIDS-associated Kaposi's sarcoma in the era of highly active antiretroviral therapy. Lancet (2006) 1.32
Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy. Cancer (2012) 1.31
A specific miRNA signature correlates with complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys (2011) 1.30
Imatinib-induced regression of AIDS-related Kaposi's sarcoma. J Clin Oncol (2004) 1.29
Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study. Br J Haematol (2015) 1.29
Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. J Clin Oncol (2009) 1.27
Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. J Antimicrob Chemother (2011) 1.26
Management of AIDS-related Kaposi's sarcoma. Lancet Oncol (2007) 1.26
Up-regulation of transforming growth factor-beta3 and extracellular matrix proteins in acquired reactive perforating collagenosis. J Am Acad Dermatol (2009) 1.26
A GWAS follow-up study reveals the association of the IL12RB2 gene with systemic sclerosis in Caucasian populations. Hum Mol Genet (2011) 1.24